Neutropenia, Severe Chronic Clinical Trial
Official title:
A Phase 2, Open-Label, Single Center, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of ANF-Rho™ in Patients With Chronic Neutropenia
| Verified date | August 2015 |
| Source | Prolong Pharmaceuticals |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
A 6 month safety, tolerability, efficacy and pharmacokinetic study with ANF-Rho to treat patients with chronic neutropenia.
| Status | Withdrawn |
| Enrollment | 0 |
| Est. completion date | October 2016 |
| Est. primary completion date | October 2016 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 1 Year and older |
| Eligibility |
Inclusion Criteria: 1. Patients 1 years of age or older 2. Patients with established chronic neutropenia defined as Median Absolute Neutrophil Count (ANC) < 0.5 x 109/L (both with and without demonstrated genetic lesion) having an indication for treatment, including: Independent of hematological parameters, all patients with: Shwachman-Diamond syndrome (SDS), Barth's syndrome or other inherited diseases associated with neutropenia (exclude Glycogen Storage Disease 1b) 3. Patients on granulocyte-colony stimulating factor (GCSF) & PEG-GCSF treatment are still eligible to participate after a washout period of 7 days, after the stopping of the drug 4. Signed and dated informed written consent/assent by the patient/parent 5. Women of childbearing potential with a negative serum pregnancy test and using a reliable method of contraception during the study period. Male study participants also agreeing to use contraception for the study period. Exclusion Criteria: 1. Evidence of chromosomal abnormalities, myelodysplasia, hematologic malignancy, aplastic anemia, systemic lupus erythematosus, or rheumatoid arthritis (Felty's syndrome) or if the neutropenia was drug-induced 2. Progressive malignant disease or malignancy history 3. Presence of macrophage activation syndrome before the diagnosis of neutropenia 4. Clinical Significant Abnormal Renal, Cardiac, Hepatic or Blood Coagulation disease. 5. Chronic infection such as hepatitis B virus (HBV), hepatitis C Virus (HCV) or Human immunodeficiency virus( HIV) or history of tuberculosis 6. Association with anemia, thrombocytopenia (low blood platelets) before the diagnosis of neutropenia. 7. Drug abuse, substance abuse, or alcohol abuse 8. Use of any other investigational drug at the time of enrollment, or within 5 half-lives prior to enrollment, whichever is longer 9. Patients unwilling and/or who are not capable of ensuring compliance with the provisions of the study protocol 10. Women who are pregnant or breastfeeding 11. Women of childbearing potential who do not use an approved method of birth control. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post ovulation methods) is not acceptable 12. Patients with known DNA loss-of-function mutations in GCSFR and RUNX1 genes |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Prolong Pharmaceuticals |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Neutrophil response rate to ANF Rho following a 6 month treatment period (induction, stabilization and maintenance periods) in patients with Chronic Neutropenia. | Median Absolute Neutrophil Count (ANC) of =1.0 x 109/L over the 6 months total treatment period | 6 months | |
| Secondary | Serum concentration of ANF-Rho over time | Pharmacokinetic parameter measuring ANF-Rho levels over time | 6 months | |
| Secondary | The peak plasma concentration of ANF-Rho after administration (Cmax) over time | Pharmacokinetic Parameter measuring ANF-Rho levels over time | 6 months | |
| Secondary | Total ANF-Rho exposure (AUC) | Pharmacokinetic parameter measuring ANF-Rho levels from time 0 through last dose. | 6 months | |
| Secondary | Time to peak plasma concentration of ANF-Rho (Tmax) | Pharmacokinetic parameter measuring the time to Cmax. | 6 months | |
| Secondary | Half-Life of ANF-Rho (T1/2) | Pharmacokinetic parameter to measure the time required for the concentration of the drug to reach half of its original value | 6 months | |
| Secondary | Rate of subject reported infection related morbidities (infections, hospitalisations and antibiotic use) in Chronic Neutropenia patients treated with ANF Rho | 6 months | ||
| Secondary | Evaluate the effect of ANF Rho on the Quality of Life and Bone Pain in Chronic Neutropenia patients. | Change in Quality of life over 6 months measured by the Short Form 36, change in bone pain over 6 months measured by the Bone Pain Questionnaire, Wong and Baker Scale and FLACC Behavioral Pain Assessment Scale | 6 months | |
| Secondary | Evaluate safety and tolerability of subcutaneous injections of ANF Rho in chronic neutropenia patients. | Composite endpoint with multiple vital signs, bone scans, biopsies, splenic ultrasounds, electrocardiographic assessments, clinical signs, and bio-analytical measures (e.g., biochemistry), and reported adverse events following repeated dosing. | 6 months |